Site Logo

News

February Newsletter
01/03/2022
Read the IGA's February newsletter.
January Newsletter
23/01/2022
Read the IGA's January newsletter
Read our new blog
04/01/2022
Our blog will allow members of the IGA board and staff to post personal reflections about their work and the activities of the IGA, as well as thoughts on rare diseases and related topics. It will be updated on an occasional basis, and links to new posts will be included on our website and in our newsletter, which you can sign up to receive here. We hope you will enjoy these personal reflections.
December newsletter
07/12/2021
Read the IGA's December newsletter
November Newsletter
09/11/2021
Read the IGA's November newsletter.
Gaucher community meets with FDA
11/10/2021
On Thursday 9th September, members of the type 2 and 3 (known as neuronopathic) Gaucher community, led by the Gaucher Community Alliance (GCA), addressed the United States Food and Drug Administration (FDA) to educate the regulators on the impact of living with neuronopathic Gaucher disease.
September newsletter
08/10/2021
Gaucher Disease Gene Therapy Focus Groups report released; American Society of Gene and Cell Therapy launches new information portal; Survey on social and medical needs of Gaucher patients; The effects of Covid-19 on the Gaucher community
August newsletter
10/08/2021
Find out about our upcoming fundraising webinar, meet our new members of staff, learn more about ERT, view a biomarkers in Gaucher disease webinar and the video of a conference on Gaucher in the Arab population, and download a new booklet on Type 2.
Ghislaine Surrel
06/08/2021
Ghislaine Surrel has passed away.
New Volunteer opportunity
16/04/2021
We are looking for a volunteer patient /patient representative to consult on home therapy research and analysis
PRESS RELEASE: GARDIAN REGISTRY LAUNCH
14/04/2021
The IGA and Kantar Health announce today the launch of the disease registry GARDIAN
PRESS RELEASE: GARDIAN REGISTRY LAUNCH
13/04/2021
PRESS RELEASE: GARDIAN REGISTRY LAUNCH
Become an IGA Volunteer
17/03/2021
Become an IGA Volunteer
February 2021 newsletter
08/03/2021
February 2021 newsletter
Gaucher disease booklet
22/02/2021
Gaucher disease booklet
PR001 in development by Prevail Therapeutics
04/02/2021
PR001 in development by Prevail Therapeutics
January 2021 newsletter
19/01/2021
January 2021 newsletter
Gene Therapy Focus Group
14/01/2021
Gene Therapy Focus Group
Vaccination program for COVID-19 in patients with Gaucher disease
14/01/2021
Vaccination program for COVID-19 in patients with Gaucher disease
A Charitable Access Program for patients with lysosomal storage disorders in underserved communities worldwide
08/01/2021
A Charitable Access Program for patients with lysosomal storage disorders in underserved communities worldwide
A Charitable Access Program for patients with lysosomal storage disorders in underserved communities worldwide
08/01/2021
A Charitable Access Program for patients with lysosomal storage disorders in underserved communities worldwide
December newsletter and office opening hours
08/12/2020
December newsletter and office opening hours
December newsletter and office opening hours
08/12/2020
December newsletter and office opening hours
WATCH NOW: Digital health technology webinar
11/11/2020
WATCH NOW: Digital health technology webinar
WATCH NOW: Digital health technology webinar
11/11/2020
WATCH NOW: Digital health technology webinar
IGA updates its Strategic Plan
10/11/2020
IGA updates its Strategic Plan
IGA updates its Strategic Plan
10/11/2020
IGA updates its Strategic Plan
WATCH NOW: New born screening webinar
04/11/2020
WATCH NOW: New born screening webinar
WATCH NOW: New born screening webinar
04/11/2020
WATCH NOW: New born screening webinar
IGA is granted Charity status
29/10/2020
IGA is granted Charity status
IGA is granted Charity status
29/10/2020
IGA is granted Charity status
Developing digital endpoints for the Gaucher community
15/10/2020
Developing digital endpoints for the Gaucher community
Developing digital endpoints for the Gaucher community
15/10/2020
Developing digital endpoints for the Gaucher community
AVAILABLE TO WATCH NOW: AAV-based gene therapy and Prevail Therapeutic's approach for neuronopathic Gaucher diseases & Parkinson's disease with a GBA mutation
15/10/2020
AVAILABLE TO WATCH NOW: AAV-based gene therapy and Prevail Therapeutic's approach for neuronopathic Gaucher diseases & Parkinson's disease with a GBA mutation
AVAILABLE TO WATCH NOW: AAV-based gene therapy and Prevail Therapeutic's approach for neuronopathic Gaucher diseases & Parkinson's disease with a GBA mutation
15/10/2020
AVAILABLE TO WATCH NOW: AAV-based gene therapy and Prevail Therapeutic's approach for neuronopathic Gaucher diseases & Parkinson's disease with a GBA mutation
Encouraging the voice of the patient in a new trial looking at in utero treatment for nGD at University of California San Francisco
13/10/2020
Encouraging the voice of the patient in a new trial looking at in utero treatment for nGD at University of California San Francisco
Encouraging the voice of the patient in a new trial looking at in utero treatment for nGD at University of California San Francisco
13/10/2020
Encouraging the voice of the patient in a new trial looking at in utero treatment for nGD at University of California San Francisco
AVAILABLE TO WATCH NOW: Ex vivo gene therapy for Type 1 Gaucher disease
05/10/2020
AVAILABLE TO WATCH NOW: Ex vivo gene therapy for Type 1 Gaucher disease
AVAILABLE TO WATCH NOW: Ex vivo gene therapy for Type 1 Gaucher disease
05/10/2020
AVAILABLE TO WATCH NOW: Ex vivo gene therapy for Type 1 Gaucher disease
AVAILABLE TO WATCH NOW: IGD Home Therapy webinar
05/10/2020
AVAILABLE TO WATCH NOW: IGD Home Therapy webinar
AVAILABLE TO WATCH NOW: IGD Home Therapy webinar
05/10/2020
AVAILABLE TO WATCH NOW: IGD Home Therapy webinar
MEMBERS REGISTER NOW for the EWGGD ECongress on 12 & 13 October
02/10/2020
MEMBERS REGISTER NOW for the EWGGD ECongress on 12 & 13 October
MEMBERS REGISTER NOW for the EWGGD ECongress on 12 & 13 October
02/10/2020
MEMBERS REGISTER NOW for the EWGGD ECongress on 12 & 13 October
AVAILABLE TO WATCH NOW - Educational webinar: EWGGD GD1 guidelines
17/09/2020
AVAILABLE TO WATCH NOW - Educational webinar: EWGGD GD1 guidelines
AVAILABLE TO WATCH NOW - Educational webinar: EWGGD GD1 guidelines
17/09/2020
AVAILABLE TO WATCH NOW - Educational webinar: EWGGD GD1 guidelines
AVAILABLE TO WATCH NOW - Educational webinar: Gaucher & Parkinson's disease
17/09/2020
AVAILABLE TO WATCH NOW - Educational webinar: Gaucher & Parkinson's disease
AVAILABLE TO WATCH NOW - Educational webinar: Gaucher & Parkinson's disease
17/09/2020
AVAILABLE TO WATCH NOW - Educational webinar: Gaucher & Parkinson's disease
A letter from Anne-Grethe Lauridsen
08/09/2020
A letter from Anne-Grethe Lauridsen
A letter from Anne-Grethe Lauridsen
08/09/2020
A letter from Anne-Grethe Lauridsen
Online events - Autumn programme
06/08/2020
Online events - Autumn programme
Online events - Autumn programme
06/08/2020
Online events - Autumn programme
Educational webinars
31/07/2020
Educational webinars
Educational webinars
31/07/2020
Educational webinars
Home therapy with enzyme replacement therapy for Gaucher disease: a short statement from the European Working Group on Gaucher Disease (EWGGD)
30/07/2020
Home therapy with enzyme replacement therapy for Gaucher disease: a short statement from the European Working Group on Gaucher Disease (EWGGD)
Home therapy with enzyme replacement therapy for Gaucher disease: a short statement from the European Working Group on Gaucher Disease (EWGGD)
30/07/2020
Home therapy with enzyme replacement therapy for Gaucher disease: a short statement from the European Working Group on Gaucher Disease (EWGGD)
IGD Home Therapy Photo Competition
22/07/2020
IGD Home Therapy Photo Competition
AVROBIO Announces New Patients Dosed in Gaucher Disease and Cystinosis Clinical Trials
06/07/2020
AVROBIO Announces New Patients Dosed in Gaucher Disease and Cystinosis Clinical Trials
Orphazyme phase 2 study of arimoclomol in Gaucher disease
24/06/2020
Orphazyme phase 2 study of arimoclomol in Gaucher disease
IGA and CENTOGENE Team Up to Ensure myLSDapp Provides the Highest Level of Patient Data Protection
15/06/2020
IGA and CENTOGENE Team Up to Ensure myLSDapp Provides the Highest Level of Patient Data Protection
COVID-19: IGA and European GD Network Gaucher Research Survey
29/05/2020
COVID-19: IGA and European GD Network Gaucher Research Survey
Minutes from IGA's Biennial General Meeting
29/05/2020
Minutes from IGA's Biennial General Meeting
The IGA initiates a global discussion on home therapy for Gaucher patients
14/05/2020
The IGA initiates a global discussion on home therapy for Gaucher patients
AVROBIO to Collaborate with Saladax Biomedical
11/05/2020
AVROBIO to Collaborate with Saladax Biomedical
COVID19 & home treatment
28/04/2020
COVID19 & home treatment
Notes from the EWGGD webinar on 1 April
14/04/2020
Notes from the EWGGD webinar on 1 April
Results of the IGA's Board Election
14/04/2020
Results of the IGA's Board Election
The IGA has co-authored 'The Definition of Neuronopathic Gaucher disease'
07/04/2020
The IGA has co-authored 'The Definition of Neuronopathic Gaucher disease'
IGA co-authors a scientific paper titled 'The road to biosimilars in rare diseases – ongoing lessons from Gaucher disease
06/04/2020
IGA co-authors a scientific paper titled 'The road to biosimilars in rare diseases – ongoing lessons from Gaucher disease
COVID-19: A statement from the EWGGD
31/03/2020
COVID-19: A statement from the EWGGD
Covid-19 - keeping in touch
30/03/2020
Covid-19 - keeping in touch
An update from the ORPHAZYME Advocacy Team
30/03/2020
An update from the ORPHAZYME Advocacy Team
An update from the TAKEDA Advocacy team
30/03/2020
An update from the TAKEDA Advocacy team
An update from the AVROBIO advocacy team
25/03/2020
An update from the AVROBIO advocacy team
IGA's membership grows to 57 member associations
23/03/2020
IGA's membership grows to 57 member associations
COVID-19 : Supporting our members
20/03/2020
COVID-19 : Supporting our members
March 2020 newsletter
18/03/2020
March 2020 newsletter
A message regarding the COVID-19 pandemic
18/03/2020
A message regarding the COVID-19 pandemic
IGA response to COVID-19: attending meetings
16/03/2020
IGA response to COVID-19: attending meetings
Good news sharing - charitable access
13/03/2020
Good news sharing - charitable access
IGA neuronopathic Gaucher Disease (nGD) Global Registry: patient community phase I final report
12/03/2020
IGA neuronopathic Gaucher Disease (nGD) Global Registry: patient community phase I final report
Postponement of IGA Biennial Meeting in response to concerns over COVID-19
10/03/2020
Postponement of IGA Biennial Meeting in response to concerns over COVID-19
Would you like to join the IGA's board of directors?
25/02/2020
Would you like to join the IGA's board of directors?
Kantar partnership announcement: Facebook Live session
05/02/2020
Kantar partnership announcement: Facebook Live session
14th European Working Group on Gaucher Disease Congress
04/02/2020
14th European Working Group on Gaucher Disease Congress
International Gaucher Alliance and Kantar Partnership announcement
03/02/2020
International Gaucher Alliance and Kantar Partnership announcement
IGA's Membership Grows to 56 Member Associations From 54 Countries
23/01/2020
IGA's Membership Grows to 56 Member Associations From 54 Countries
AVROBIO Announces Clinical and Regulatory Progress for Gaucher Disease Program
15/01/2020
AVROBIO Announces Clinical and Regulatory Progress for Gaucher Disease Program
PR001 Administered to International Type 2 Gaucher Disease Patient Via Compassionate Use Pathway
10/01/2020
PR001 Administered to International Type 2 Gaucher Disease Patient Via Compassionate Use Pathway
Prevail Therapeutics is recruiting patients for PROPEL, a clinical trial testing an investigational gene therapy called PR001 to treat Parkinson’s disease in people with GBA mutations
08/01/2020
Prevail Therapeutics is recruiting patients for PROPEL, a clinical trial testing an investigational gene therapy called PR001 to treat Parkinson’s disease in people with GBA mutations
December 2019 newsletter
17/12/2019
December 2019 newsletter
IGA's membership grows to 55 member associations from 54 countries
12/12/2019
IGA's membership grows to 55 member associations from 54 countries
November 2019 newsletter
28/11/2019
November 2019 newsletter
IGA appoints a new co-opted board member
30/10/2019
IGA appoints a new co-opted board member
October 2019 newsletter
24/10/2019
October 2019 newsletter
Children from India receiving ERT
11/10/2019
Children from India receiving ERT
IGA advocates to get treatment to a young child in Kenya - letter of thanks
10/10/2019
IGA advocates to get treatment to a young child in Kenya - letter of thanks
Understanding the impact of being diagnosed with a comorbidity
10/10/2019
Understanding the impact of being diagnosed with a comorbidity
Happy International Gaucher Day
01/10/2019
Happy International Gaucher Day
September 2019 newsletter
26/09/2019
September 2019 newsletter
Regional Managers visit BP Koirala Hospital in Dharan, Nepal
11/09/2019
Regional Managers visit BP Koirala Hospital in Dharan, Nepal
Over 53 paediatricians attend event hosted by IGA in Kathmandu
10/09/2019
Over 53 paediatricians attend event hosted by IGA in Kathmandu
Regional Managers organise LSD patient meeting in Kathmandu
09/09/2019
Regional Managers organise LSD patient meeting in Kathmandu
Regional Managers organise medical programme in Nepal
06/09/2019
Regional Managers organise medical programme in Nepal
Orphazyme complete enrolment in Phase II clinical trial
30/08/2019
Orphazyme complete enrolment in Phase II clinical trial
August 2019 newsletter
29/08/2019
August 2019 newsletter
IGA expands its global reach to Central America
07/08/2019
IGA expands its global reach to Central America
Sanofi Genzyme provide ERT to three Sudanese children through their Charitable Access Programme
06/08/2019
Sanofi Genzyme provide ERT to three Sudanese children through their Charitable Access Programme
Six year old Tanzanian child gets treatment
06/08/2019
Six year old Tanzanian child gets treatment
New Croatian Gaucher Association joins the IGA
22/07/2019
New Croatian Gaucher Association joins the IGA
IGD Press Release
17/07/2019
IGD Press Release
nGD poster presentation at the EWGGD
08/07/2019
nGD poster presentation at the EWGGD
Jeremy Manuel is the IGA's rare star for IGD2019
04/07/2019
Jeremy Manuel is the IGA's rare star for IGD2019
July Newsletter (IGD)
04/07/2019
July Newsletter (IGD)
Brazil to join the IGA
26/06/2019
Brazil to join the IGA
June newsletter
24/06/2019
June newsletter
ORDER YOUR #IGD2019 TATTOOS - MEMBERS ONLY
04/06/2019
ORDER YOUR #IGD2019 TATTOOS - MEMBERS ONLY
NOMINATE YOUR RARE STAR FOR #IGD2019
04/06/2019
NOMINATE YOUR RARE STAR FOR #IGD2019
International Gaucher Day 2019 #IGD2019
31/05/2019
International Gaucher Day 2019 #IGD2019
May newsletter
28/05/2019
May newsletter
April newsletter
25/04/2019
April newsletter
AVROBIO explore gene therapy as a potential treatment for Gaucher disease
10/04/2019
AVROBIO explore gene therapy as a potential treatment for Gaucher disease
IGA appoints a new co-opted member to its board
09/04/2019
IGA appoints a new co-opted member to its board
March newsletter
26/03/2019
March newsletter
Election of new Chair and Vice-Chair
06/03/2019
Election of new Chair and Vice-Chair
February newsletter
28/02/2019
February newsletter
Pascal Niemeyer resigns as IGA Chairman and Director
13/02/2019
Pascal Niemeyer resigns as IGA Chairman and Director
Australia & New Zealand to join the IGA
12/02/2019
Australia & New Zealand to join the IGA
Looking for Volunteers
22/01/2019
Looking for Volunteers
January 2019 newsletter
22/01/2019
January 2019 newsletter
Global Patient Registry for nGD
14/01/2019
Global Patient Registry for nGD
December newsletter
18/12/2018
December newsletter
Mongolia to join the IGA
10/12/2018
Mongolia to join the IGA
November newsletter
30/11/2018
November newsletter
Minutes from the EGA's Biennial Members Meeting
21/11/2018
Minutes from the EGA's Biennial Members Meeting
October newsletter
01/11/2018
October newsletter
EWGGD 2019 'Save the Date'
24/10/2018
EWGGD 2019 'Save the Date'
The EGA becomes the IGA
14/10/2018
The EGA becomes the IGA
#IGD2018 #rarestars videos
02/10/2018
#IGD2018 #rarestars videos
September newsletter
24/09/2018
September newsletter
Turkey and Kazakhstan to join the EGA
11/09/2018
Turkey and Kazakhstan to join the EGA
August Newsletter
12/08/2018
August Newsletter
Biennial Members Meeting – 15 & 16 October 2018
04/07/2018
Biennial Members Meeting – 15 & 16 October 2018
Results of EGA 2018/2020 Election
27/06/2018
Results of EGA 2018/2020 Election
Morocco to join the EGA
21/06/2018
Morocco to join the EGA
GDPR Changes. Tell us how you want to be contacted.
30/04/2018
GDPR Changes. Tell us how you want to be contacted.
Pakistan to join the EGA
22/04/2018
Pakistan to join the EGA
EGA Board Membership Opportunities
10/04/2018
EGA Board Membership Opportunities
Advocacy training grant
10/04/2018
Advocacy training grant
Important Changes to Data Protection.
07/02/2018
Important Changes to Data Protection.
Rare Disease Day Video 2018
30/01/2018
Rare Disease Day Video 2018
Rare Disease Day 2018 28 February
15/01/2018
Rare Disease Day 2018 28 February
Seasons Greetings and Office Opening Hours
19/12/2017
Seasons Greetings and Office Opening Hours
International Gaucher Day 2017. A great success.
03/10/2017
International Gaucher Day 2017. A great success.
A further Inspiring #IGD2017 tale for you to enjoy.
27/09/2017
A further Inspiring #IGD2017 tale for you to enjoy.
3rd IGD 2017 story for you to enjoy!
22/09/2017
3rd IGD 2017 story for you to enjoy!
2nd Inspiring story for IGD 2017 published
19/09/2017
2nd Inspiring story for IGD 2017 published
IGD2017
12/09/2017
IGD2017
Go with gaucher
20/07/2017
Go with gaucher
Clinical Trial for Gaucher Disease Type 3
22/02/2017
Clinical Trial for Gaucher Disease Type 3
Seasons Greetings/Office opening hours
16/12/2016
Seasons Greetings/Office opening hours
Botswana to join the EGA
29/11/2016
Botswana to join the EGA
Go With Gaucher, taking forward the next generation: how to involve young people to create a new generation of patient advocates
03/11/2016
Go With Gaucher, taking forward the next generation: how to involve young people to create a new generation of patient advocates
Your opinion about an app to report side-effects and receive safety information
07/09/2016
Your opinion about an app to report side-effects and receive safety information
A new Korean ERT 'Abcertin' - Important Information for doctors treating Gaucher patients
30/08/2016
A new Korean ERT 'Abcertin' - Important Information for doctors treating Gaucher patients
Spotlight on Gaucher 2016 Campaign
28/08/2016
Spotlight on Gaucher 2016 Campaign
Change to the constitution: Members Vote paves the way to the EGA becoming global
18/07/2016
Change to the constitution: Members Vote paves the way to the EGA becoming global
EGA announces new chairman
18/07/2016
EGA announces new chairman
Dr Roscoe Brady
20/06/2016
Dr Roscoe Brady
Guatemala and Japan to join the EGA
13/04/2016
Guatemala and Japan to join the EGA
EGA GOES TO SOUTH AFRICA
13/04/2016
EGA GOES TO SOUTH AFRICA
Launch of the Official Website of the 12th EWGGD Meeting In Zaragoza, Spain
17/03/2016
Launch of the Official Website of the 12th EWGGD Meeting In Zaragoza, Spain
Shire marks 30th Anniversary with Innovative Global Program to benefit children with Rare Diseases
17/02/2016
Shire marks 30th Anniversary with Innovative Global Program to benefit children with Rare Diseases
China to join the EGA
10/02/2016
China to join the EGA
The Patient Group Handbook: A Practical Guide for Research and Drug Development
11/01/2016
The Patient Group Handbook: A Practical Guide for Research and Drug Development
The Psychosocial and Neurocognitive Impacts of Gaucher Disease, Type 1 on Pediatric and Young Adult Patients
23/11/2015
The Psychosocial and Neurocognitive Impacts of Gaucher Disease, Type 1 on Pediatric and Young Adult Patients
Launch of the 'Spotlight on Gaucher Film Contest'
15/07/2015
Launch of the 'Spotlight on Gaucher Film Contest'
UK Gauchers Association Granted a Positive Opinion For Orphan Designation For Gene Therapy For Gaucher Disease
27/02/2015
UK Gauchers Association Granted a Positive Opinion For Orphan Designation For Gene Therapy For Gaucher Disease
Watch the Official Rare Disease Day 2015 Video!
17/02/2015
Watch the Official Rare Disease Day 2015 Video!
European Commission Grants Marketing Authorization for Cerdelga (eliglustat), Genzyme`s oral therapy for Gaucher Disease Type 1
23/01/2015
European Commission Grants Marketing Authorization for Cerdelga (eliglustat), Genzyme`s oral therapy for Gaucher Disease Type 1
European CHMP Adopts Positive Opinion for Genzyme's Cerdelga (eliglustat) Capsules
23/11/2014
European CHMP Adopts Positive Opinion for Genzyme's Cerdelga (eliglustat) Capsules
Genzyme Announces Launch of `Expression of Hope III` Program to Build Awareness of Lysosomal Storage Disorders Through Works of Art
16/09/2014
Genzyme Announces Launch of `Expression of Hope III` Program to Build Awareness of Lysosomal Storage Disorders Through Works of Art
FDA Approval of Pediatric Indication for ELELYSO (taliglucerase alfa)
28/08/2014
FDA Approval of Pediatric Indication for ELELYSO (taliglucerase alfa)
FDA Approves Genzyme's Cerdelga (eliglustat) Capsules
20/08/2014
FDA Approves Genzyme's Cerdelga (eliglustat) Capsules
Joint proposal to facilitate clinical investigation of new medicines for Gaucher disease in children
17/05/2014
Joint proposal to facilitate clinical investigation of new medicines for Gaucher disease in children
FDA Grants Priority Review for Cerdelga (Eliglustat)
16/12/2013
FDA Grants Priority Review for Cerdelga (Eliglustat)
Ega becomes full member of EURORDIS
28/11/2013
Ega becomes full member of EURORDIS
Luxembourg to join the EGA
27/11/2013
Luxembourg to join the EGA
Moldova to join the EGA as 40th member
19/09/2013
Moldova to join the EGA as 40th member
6th nGD Family Conference, 8-10.11.2013 in Reading, UK.
02/07/2013
6th nGD Family Conference, 8-10.11.2013 in Reading, UK.
Croatia to join the EGA
18/06/2013
Croatia to join the EGA
Paraguay to join the EGA
11/06/2013
Paraguay to join the EGA
Report from regional patient meeting in Sarajevo, Bosnia & Herzegovina
20/04/2013
Report from regional patient meeting in Sarajevo, Bosnia & Herzegovina
Canada to join the EGA
26/03/2013
Canada to join the EGA
Alert for Gaucher Patients and Families regarding Zavesca Getz Product
14/12/2012
Alert for Gaucher Patients and Families regarding Zavesca Getz Product
EC denies Taliglucerase (Elelyso) market approval for Type 1 GD
06/11/2012
EC denies Taliglucerase (Elelyso) market approval for Type 1 GD
Genzyme Phase 3 Study of Eliglustat Meets Primary Endpoint
18/10/2012
Genzyme Phase 3 Study of Eliglustat Meets Primary Endpoint
Market approval of Elelyso by the Israeli Ministry of Health
03/10/2012
Market approval of Elelyso by the Israeli Ministry of Health
India to join the EGA
27/09/2012
India to join the EGA
Mexico to join the EGA
24/05/2012
Mexico to join the EGA
Bosnia & Herzegovina to join EGA
03/05/2012
Bosnia & Herzegovina to join EGA
FDA approved Elelyso (taliglucerase alfa)
01/05/2012
FDA approved Elelyso (taliglucerase alfa)
Macedonia and Switzerland to join EGA
19/04/2012
Macedonia and Switzerland to join EGA
Humanitarian Aid (March 2012)
26/03/2012
Humanitarian Aid (March 2012)
Shire Announces European Approval of Manufacturing Facility for VPRIV
22/02/2012
Shire Announces European Approval of Manufacturing Facility for VPRIV
Press release - Genzyme: Four-Year Data from Phase 2 Trial ...
09/02/2012
Press release - Genzyme: Four-Year Data from Phase 2 Trial ...
Press release: Protalix Announces New Clinical Data on Taliglucerase Alfa
09/02/2012
Press release: Protalix Announces New Clinical Data on Taliglucerase Alfa
EGA is now officially eligible to be involved in the acitivities of the EMA
21/12/2011
EGA is now officially eligible to be involved in the acitivities of the EMA
1st Regional Patient Meeting in Slovenia
21/11/2011
1st Regional Patient Meeting in Slovenia
New EGA Website launched
01/11/2011
New EGA Website launched
Cerezyme Emergency Treatment Program (CETP)
04/01/2011
Cerezyme Emergency Treatment Program (CETP)
Achive